Brain-stimulation timing decides cognition for GBA1 Parkinson's patients

The team pooled longitudinal clinical and cognitive records from 343 patients at ten academic centers in the United States and Europe, then split them by GBA1 status and by whether their stimulation came early or late in the disease ^[6][13]. The dividing line was roughly seven to eight years after diagnosis ^[1]. Among carriers, surgery before that mark went with slower memory and executive decline, and surgery after it with a steeper drop ^[2][3]. Among patients without the mutation, when the surgery happened made no difference ^[7].

That non-carrier comparison matters. If the stimulation itself were damaging cognition, you would expect late surgery to hurt everyone who had it. It hurt only the people whose genetics already push them toward dementia. On that basis the authors conclude the operation itself does not accelerate cognitive decline, and that timing is what matters for carriers ^[11].

What the study cannot do is prove that moving surgery earlier would change the outcome. This is pooled observational data, not a randomized trial ^[13]. Patients who reach surgery late are, by definition, further along in the disease, and may differ from early patients in ways the comparison does not capture. The association is consistent across all ten sites ^[6]. The causal arrow is still an inference.

The published summary calls the late-surgery decline "significantly faster and steeper" without saying by how much ^[3]. Until that gap is quantified, a clinician cannot weigh it against the real risks of operating on a patient earlier than they otherwise would.

For GBA1 carriers the stakes are specific. DBS places thin electrodes in the brain's motor hubs and drives them with mild pulses from an implanted neurostimulator, steadying tremor and rigidity when the usual drugs become inconsistent ^[16]. Carriers tend to develop aggressive motor symptoms young, which makes them good candidates for that surgery, and they are also prone to earlier, more severe cognitive loss, which has made some clinicians wary of operating at all ^[8][9]. The authors argue that a GBA1 result should not rule a patient out; it should move testing and surgery earlier ^[12].

"The future of DBS may not simply be deciding who should receive it, but identifying the right window to intervene for each individual patient," said Gian Pal, co-lead author and chief of neurology at the Hackensack Meridian Neuroscience Institute at JFK University Medical Center ^[14][15].